Article: Bumetanide

Bumetanide
Systematic (IUPAC) name
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
Identifiers
CAS number	28395-03-1
ATC code	C03CA02
PubChem	2471
DrugBank	APRD00294
Chemical data
Formula	C17H20N2O5S
Mol. weight	364.417 g/mol
Pharmacokinetic data
Bioavailability	almost complete
Protein binding	97%
Metabolism	hepatic
Half life	60-90 minutes
Excretion	renal
Therapeutic considerations
Pregnancy cat.	C (Australia)
Legal status	S4 (Aust); POM (UK)
Routes	oral

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. Furosemide is incompletely absorbed in the intestine (40%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

It is marketed by Hoffmann-La Roche with the brand name Bumex.